NEW YORK/TOKYO -- Pharmaceutical goods linked to forced labor in China's Xinjiang region are making their way to Japan and the U.S. despite efforts by those countries to block such imports, trade data and a new study show.
Japan's Pharmaceutical and Medical Devices Agency (PMDA) and the U.S. Food and Drug Administration license two Xinjiang-linked pharmaceutical producers each, according to a report published Tuesday by global security nonprofit C4ADS.





.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)